{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:28:41Z","timestamp":1790706521913,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:00:00Z","timestamp":1530144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000341","name":"Arthritis Research UK","doi-asserted-by":"publisher","award":["18825"],"award-info":[{"award-number":["18825"]}],"id":[{"id":"10.13039\/501100000341","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To analyze the Routine Assessment of Patient Index Data 3 (<jats:styled-content style=\"fixed-case\">RAPID<\/jats:styled-content>3), a patient\u2010reported, composite index, designed initially for feasibility in clinical care. <jats:styled-content style=\"fixed-case\">RAPID<\/jats:styled-content>3 was developed in rheumatoid arthritis, but has been found useful in many rheumatic diseases. We analyzed <jats:styled-content style=\"fixed-case\">RAPID<\/jats:styled-content>3 in patients with psoriatic arthritis (PsA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Post hoc analyses were performed on 2 independent data sets, the Tight Control of Psoriatic Arthritis (<jats:styled-content style=\"fixed-case\">TICOPA<\/jats:styled-content>) clinical trial, and the Long\u2010Term Outcome in Psoriatic Arthritis Study (<jats:styled-content style=\"fixed-case\">LOPAS II<\/jats:styled-content>), an observational cohort. <jats:styled-content style=\"fixed-case\">RAPID<\/jats:styled-content>3 (range 0\u201330) is the total of three 0\u201310 scores for the Health Assessment Questionnaire disability index (recalculated from 0\u20133), pain visual analog scale (<jats:styled-content style=\"fixed-case\">VAS<\/jats:styled-content>), and global <jats:styled-content style=\"fixed-case\">VAS<\/jats:styled-content>. <jats:styled-content style=\"fixed-case\">RAPID<\/jats:styled-content>3 scores were compared to the Psoriatic Arthritis Disease Activity Score (<jats:styled-content style=\"fixed-case\">PASDAS<\/jats:styled-content>), the Disease Activity in Psoriatic Arthritis (<jats:styled-content style=\"fixed-case\">DAPSA<\/jats:styled-content>), and other available clinical measures, according to Spearman's correlation coefficients, standardized response mean, <jats:styled-content style=\"fixed-case\">SEM<\/jats:styled-content>, smallest detectible difference, minimally important difference (in patients who improved), and receiver operating characteristic curves. <jats:styled-content style=\"fixed-case\">RAPID<\/jats:styled-content>3 remission was compared to criteria for both standard minimal disease activity (<jats:styled-content style=\"fixed-case\">MDA<\/jats:styled-content>) and very low disease activity (<jats:styled-content style=\"fixed-case\">VLDA<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">RAPID<\/jats:styled-content>3 was correlated significantly with <jats:styled-content style=\"fixed-case\">PASDAS<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">TICOPA<\/jats:styled-content> (r = 0.79, <jats:italic>P<\/jats:italic> &lt; 0.01) and with <jats:styled-content style=\"fixed-case\">DAPSA<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">LOPAS II<\/jats:styled-content> (\u03c1 = 0.59, <jats:italic>P<\/jats:italic> &lt; 0.01), and with most other measures in both data sets. <jats:styled-content style=\"fixed-case\">RAPID<\/jats:styled-content>3 discriminated between tight control and standard care in <jats:styled-content style=\"fixed-case\">TICOPA<\/jats:styled-content> at 48 weeks at levels comparable to <jats:styled-content style=\"fixed-case\">DAPSA<\/jats:styled-content> and the <jats:styled-content style=\"fixed-case\">PASDAS<\/jats:styled-content> (<jats:italic>P<\/jats:italic> &lt; 0.01). <jats:styled-content style=\"fixed-case\">RAPID<\/jats:styled-content>3 remission discriminated treatment groups in <jats:styled-content style=\"fixed-case\">TICOPA<\/jats:styled-content> intermediate between <jats:styled-content style=\"fixed-case\">MDA<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">VLDA<\/jats:styled-content> criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">RAPID<\/jats:styled-content>3 appears comparably informative to <jats:styled-content style=\"fixed-case\">PASDAS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">DAPSA<\/jats:styled-content> in PsA, with greater feasibility for routine clinical care.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.23460","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T12:02:37Z","timestamp":1510056157000},"page":"1198-1205","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight\u2010Control Clinical Trial and an Observational Cohort"],"prefix":"10.1002","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C.","family":"Coates","sequence":"first","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine and Leeds Teaching Hospitals NHS Trust, Leeds and University of Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tillett","sequence":"additional","affiliation":[{"name":"Royal National Hospital for Rheumatic Diseases and University of Bath Bath UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Shaddick","sequence":"additional","affiliation":[{"name":"University of Bath Bath UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Pincus","sequence":"additional","affiliation":[{"name":"Rush University School of Medicine Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[{"name":"University of California at San Diego School of Medicine San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S.","family":"Helliwell","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine University of Leeds and Leeds Teaching Hospitals NHS Trust Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,6,28]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208617"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.007"},{"key":"e_1_2_6_4_1","first-page":"86","article-title":"World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials","volume":"41","author":"Boers M","year":"1994","journal-title":"J Rheumatol Suppl"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.008"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_6_7_1","first-page":"2146","article-title":"An index of patient reported outcomes (PRO\u2010Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis","volume":"33","author":"Pincus T","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000277"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2827-4"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3256-7"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000235"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/00913847.2015.1074852"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3182936b98"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101091"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.017"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123582"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2921-2"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu264"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00347-5"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201341"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122259"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780261107"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080182"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150826"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20162"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20155"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22576"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203419"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121059"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141586"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90837-8"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem364"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22443"},{"key":"e_1_2_6_36_1","first-page":"201","article-title":"Relative efficiencies of physician\/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials","volume":"35","author":"Pincus T","year":"2008","journal-title":"J Rheumatol"},{"issue":"85","key":"e_1_2_6_37_1","first-page":"S47","article-title":"Relative efficiencies of the 7 rheumatoid arthritis core data set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents","volume":"32","author":"Pincus T","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151491"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.097345"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140172"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207507"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.23460","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.23460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:31:36Z","timestamp":1759415496000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.23460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,28]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1002\/acr.23460"],"URL":"https:\/\/doi.org\/10.1002\/acr.23460","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,28]]},"assertion":[{"value":"2017-05-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}